NOVONESIS (NOVOZYMES) B (NZM2.DE) Stock Fundamental Analysis

FRA:NZM2 • DK0060336014

50.26 EUR
+0.39 (+0.78%)
Last: Feb 27, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

4

Taking everything into account, NZM2 scores 4 out of 10 in our fundamental rating. NZM2 was compared to 66 industry peers in the Chemicals industry. NZM2 has only an average score on both its financial health and profitability. NZM2 has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year NZM2 was profitable.
  • Of the past 5 years NZM2 4 years were profitable.
  • NZM2 had a positive operating cash flow in 4 of the past 5 years.
NZM2.DE Yearly Net Income VS EBIT VS OCF VS FCFNZM2.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

1.2 Ratios

  • The Return On Assets of NZM2 (4.31%) is better than 60.61% of its industry peers.
  • NZM2's Return On Equity of 6.54% is in line compared to the rest of the industry. NZM2 outperforms 59.09% of its industry peers.
  • With a Return On Invested Capital value of 5.66%, NZM2 perfoms like the industry average, outperforming 59.09% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for NZM2 is above the industry average of 6.95%.
  • The 3 year average ROIC (11.83%) for NZM2 is well above the current ROIC(5.66%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 4.31%
ROE 6.54%
ROIC 5.66%
ROA(3y)8.6%
ROA(5y)10.46%
ROE(3y)16.98%
ROE(5y)20.54%
ROIC(3y)11.83%
ROIC(5y)13.54%
NZM2.DE Yearly ROA, ROE, ROICNZM2.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

1.3 Margins

  • The Profit Margin of NZM2 (13.61%) is better than 95.45% of its industry peers.
  • In the last couple of years the Profit Margin of NZM2 has declined.
  • With an excellent Operating Margin value of 21.89%, NZM2 belongs to the best of the industry, outperforming 95.45% of the companies in the same industry.
  • NZM2's Operating Margin has declined in the last couple of years.
  • NZM2 has a better Gross Margin (52.79%) than 78.79% of its industry peers.
  • In the last couple of years the Gross Margin of NZM2 has declined.
Industry RankSector Rank
OM 21.89%
PM (TTM) 13.61%
GM 52.79%
OM growth 3Y-13.18%
OM growth 5Y-7.58%
PM growth 3Y-27.63%
PM growth 5Y-18.32%
GM growth 3Y-6.52%
GM growth 5Y-3.21%
NZM2.DE Yearly Profit, Operating, Gross MarginsNZM2.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • NZM2 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • NZM2 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NZM2.DE Yearly Shares OutstandingNZM2.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
NZM2.DE Yearly Total Debt VS Total AssetsNZM2.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

  • An Altman-Z score of 3.80 indicates that NZM2 is not in any danger for bankruptcy at the moment.
  • NZM2 has a better Altman-Z score (3.80) than 74.24% of its industry peers.
  • NZM2 has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
  • NZM2 has a better Debt to Equity ratio (0.26) than 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Altman-Z 3.8
ROIC/WACC0.79
WACC7.16%
NZM2.DE Yearly LT Debt VS Equity VS FCFNZM2.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.3 Liquidity

  • A Current Ratio of 1.61 indicates that NZM2 should not have too much problems paying its short term obligations.
  • NZM2 has a Current ratio of 1.61. This is comparable to the rest of the industry: NZM2 outperforms 50.00% of its industry peers.
  • A Quick Ratio of 1.00 indicates that NZM2 should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.00, NZM2 is in line with its industry, outperforming 43.94% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.61
Quick Ratio 1
NZM2.DE Yearly Current Assets VS Current LiabilitesNZM2.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • Measured over the past 5 years, NZM2 shows a small growth in Earnings Per Share. The EPS has been growing by 5.14% on average per year.
EPS 1Y (TTM)N/A
EPS 3Y-0.9%
EPS 5Y5.14%
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-50.8%

3.2 Future

  • The Earnings Per Share is expected to grow by 11.28% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 6.72% on average over the next years.
EPS Next Y17.73%
EPS Next 2Y14.64%
EPS Next 3Y13.53%
EPS Next 5Y11.28%
Revenue Next Year6.98%
Revenue Next 2Y7.08%
Revenue Next 3Y7.71%
Revenue Next 5Y6.72%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NZM2.DE Yearly Revenue VS EstimatesNZM2.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B
NZM2.DE Yearly EPS VS EstimatesNZM2.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 29.05, NZM2 can be considered very expensive at the moment.
  • NZM2's Price/Earnings ratio is in line with the industry average.
  • NZM2's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.07.
  • NZM2 is valuated rather expensively with a Price/Forward Earnings ratio of 24.72.
  • NZM2's Price/Forward Earnings is on the same level as the industry average.
  • When comparing the Price/Forward Earnings ratio of NZM2 to the average of the S&P500 Index (28.05), we can say NZM2 is valued inline with the index average.
Industry RankSector Rank
PE 29.05
Fwd PE 24.72
NZM2.DE Price Earnings VS Forward Price EarningsNZM2.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • NZM2's Enterprise Value to EBITDA ratio is in line with the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 13.66
NZM2.DE Per share dataNZM2.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20 25

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • NZM2 has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as NZM2's earnings are expected to grow with 13.53% in the coming years.
PEG (NY)1.64
PEG (5Y)5.65
EPS Next 2Y14.64%
EPS Next 3Y13.53%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

2

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 1.75%, NZM2 has a reasonable but not impressive dividend return.
  • Compared to an average industry Dividend Yield of 2.21, NZM2 has a dividend in line with its industry peers.
  • NZM2's Dividend Yield is comparable with the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 1.75%

5.2 History

  • The dividend of NZM2 decreases each year by -33.21%.
Dividend Growth(5Y)-33.21%
Div Incr YearsN/A
Div Non Decr YearsN/A
NZM2.DE Yearly Dividends per shareNZM2.DE Yearly Dividends per shareYearly Dividends per share 2022 2026 1 2 3 4 5

5.3 Sustainability

  • NZM2 pays out 92.84% of its income as dividend. This is not a sustainable payout ratio.
DP92.84%
EPS Next 2Y14.64%
EPS Next 3Y13.53%
NZM2.DE Yearly Income VS Free CF VS DividendNZM2.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B
NZM2.DE Dividend Payout.NZM2.DE Dividend Payout, showing the Payout Ratio.NZM2.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

NOVONESIS (NOVOZYMES) B

FRA:NZM2 (2/27/2026, 7:00:00 PM)

50.26

+0.39 (+0.78%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)02-25
Earnings (Next)05-05
Inst Owners38.75%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap20.84B
Revenue(TTM)N/A
Net Income(TTM)702.70M
Analysts72.17
Price Target63.75 (26.84%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.75%
Yearly Dividend0.67
Dividend Growth(5Y)-33.21%
DP92.84%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.87%
Min EPS beat(2)14.06%
Max EPS beat(2)45.68%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.78%
Min Revenue beat(2)-2.26%
Max Revenue beat(2)-1.31%
Revenue beat(4)2
Avg Revenue beat(4)24.14%
Min Revenue beat(4)-2.26%
Max Revenue beat(4)99.78%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.57%
PT rev (3m)-0.6%
EPS NQ rev (1m)-16.05%
EPS NQ rev (3m)-36.08%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.43%
Revenue NQ rev (1m)1.88%
Revenue NQ rev (3m)-1.15%
Revenue NY rev (1m)-0.85%
Revenue NY rev (3m)-0.59%
Valuation
Industry RankSector Rank
PE 29.05
Fwd PE 24.72
P/S 4.04
P/FCF N/A
P/OCF N/A
P/B 1.94
P/tB N/A
EV/EBITDA 13.66
EPS(TTM)1.73
EY3.44%
EPS(NY)2.03
Fwd EY4.05%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS12.45
BVpS25.92
TBVpS-1.03
PEG (NY)1.64
PEG (5Y)5.65
Graham Number31.76
Profitability
Industry RankSector Rank
ROA 4.31%
ROE 6.54%
ROCE 7.49%
ROIC 5.66%
ROICexc 5.78%
ROICexgc 23.66%
OM 21.89%
PM (TTM) 13.61%
GM 52.79%
FCFM N/A
ROA(3y)8.6%
ROA(5y)10.46%
ROE(3y)16.98%
ROE(5y)20.54%
ROIC(3y)11.83%
ROIC(5y)13.54%
ROICexc(3y)18.53%
ROICexc(5y)19.75%
ROICexgc(3y)31.28%
ROICexgc(5y)31.84%
ROCE(3y)15.67%
ROCE(5y)17.93%
ROICexgc growth 3Y-32.98%
ROICexgc growth 5Y-9.18%
ROICexc growth 3Y-47.62%
ROICexc growth 5Y-27.9%
OM growth 3Y-13.18%
OM growth 5Y-7.58%
PM growth 3Y-27.63%
PM growth 5Y-18.32%
GM growth 3Y-6.52%
GM growth 5Y-3.21%
F-ScoreN/A
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Debt/EBITDA 1.62
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.61
Quick Ratio 1
Altman-Z 3.8
F-ScoreN/A
WACC7.16%
ROIC/WACC0.79
Cap/Depr(3y)134.29%
Cap/Depr(5y)112.94%
Cap/Sales(3y)12.45%
Cap/Sales(5y)10.47%
Profit Quality(3y)105.18%
Profit Quality(5y)105.22%
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3Y-0.9%
EPS 5Y5.14%
EPS Q2Q%N/A
EPS Next Y17.73%
EPS Next 2Y14.64%
EPS Next 3Y13.53%
EPS Next 5Y11.28%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-50.8%
Revenue Next Year6.98%
Revenue Next 2Y7.08%
Revenue Next 3Y7.71%
Revenue Next 5Y6.72%
EBIT growth 1Y10.22%
EBIT growth 3Y7.76%
EBIT growth 5Y-29.04%
EBIT Next Year63.27%
EBIT Next 3Y24.57%
EBIT Next 5Y17.53%
FCF growth 1Y135.14%
FCF growth 3Y20.37%
FCF growth 5Y-21.39%
OCF growth 1Y83.4%
OCF growth 3Y23.25%
OCF growth 5Y-20.42%

NOVONESIS (NOVOZYMES) B / NZM2.DE FAQ

What is the ChartMill fundamental rating of NOVONESIS (NOVOZYMES) B (NZM2.DE) stock?

ChartMill assigns a fundamental rating of 4 / 10 to NZM2.DE.


What is the valuation status for NZM2 stock?

ChartMill assigns a valuation rating of 2 / 10 to NOVONESIS (NOVOZYMES) B (NZM2.DE). This can be considered as Overvalued.


What is the profitability of NZM2 stock?

NOVONESIS (NOVOZYMES) B (NZM2.DE) has a profitability rating of 5 / 10.


What is the earnings growth outlook for NOVONESIS (NOVOZYMES) B?

The Earnings per Share (EPS) of NOVONESIS (NOVOZYMES) B (NZM2.DE) is expected to grow by 17.73% in the next year.


Can you provide the dividend sustainability for NZM2 stock?

The dividend rating of NOVONESIS (NOVOZYMES) B (NZM2.DE) is 2 / 10 and the dividend payout ratio is 92.84%.